James Ferguson, MD Joins The Medicines Company as Vice President, Global Medical, Surgical and Critical Care

The Medicines Company (NASDAQ:MDCO) today announced that Dr. James Ferguson has joined the Company as Vice President, Global Medical, Surgical and Critical Care. Dr. Ferguson’s first charge will be leading medical science/affairs strategies and activities supporting the Company’s anticipated launch of CleviprexTM (clevidipine butyrate injectable emulsion), a novel investigational IV antihypertensive. "I am thrilled to be joining the team at The Medicines Company, and even more thrilled to be working with an important new product like Cleviprex,” said Dr. Ferguson. "As a clinical investigator for more than 20 years, I fully appreciate the unmet medical needs in acute cardiac care medicine, and feel that Cleviprex is uniquely poised to help physicians meet the pressing need for improved acute hypertension treatment options once approved by FDA. I look forward to playing a leading role in helping to shape the future of both The Medicines Company and acute care medicine as we work to bring this and other much needed therapies to market. ” Dr. Ferguson is widely recognized as a leading acute care and cardiovascular researcher. He has been at the Texas Heart Institute at St. Luke’s Episcopal Hospital since 1987. Dr. Ferguson was most recently Associate Director, Clinical Cardiology Research at the Texas Heart Institute, and Co- Director of the Cardiology Fellowship Training Program at St. Luke's Episcopal Hospital in Houston, TX. He was also Associate Professor in Medicine, Baylor College of Medicine and Clinical Assistant Professor at the University of Texas Health Science Center at Houston. Dr. Ferguson has authored more than 260 peer reviewed papers, 25 book chapters, 150 abstract presentations, and a textbook. He was the lead investigator for the NICE-3 study, co-primary investigator of SYNERGY, co-primary investigator for LANCELOT trials, and has served on the Steering Committees of numerous large clinical trials, including EPILOG, ORBIT, EXCITE, OPUS, PRESTO, BRAVO and CHAMPION. He has lectured internationally in 25 countries, and is widely recognized for his communication skills. "Dr. Ferguson joins us at an important time for The Medicines Company, as we focus this year on growing into a global organization and bringing our second product to market,” said Clive Meanwell, Chairman and CEO of The Medicines Company. "His unparalleled experience in the acute cardiac care arena, coupled with his deep experience in building clinical trial programs, will be critical in driving our success as a clinical and commercial organization.” MDCO-G About The Medicines Company The Medicines Company (NASDAQ: MDCO) is committed to delivering innovative, cost-effective acute care products in the worldwide hospital marketplace. The Company markets Angiomax® / Angiox® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, CleviprexTM (clevidipine butyrate injectable emulsion) and cangrelor. The Company's website is www.themedicinescompany.com. Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether clinical trial results will warrant submission of applications for regulatory approval, whether the Company will be able to obtain regulatory approvals, whether physicians, patients and other key decision-makers will accept clinical trial results, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on November 8, 2007, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.